The U.S. FDA has expanded the indication for pirtobrutinib (Jaypirca; Eli Lilly and Company) to include adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion.
Pirtobrutinib was already approved in the United States for relapsed or refractory CLL/SLL after prior treatment with a covalent BTK inhibitor. The October 2, 2026 decision moves the non-covalent Bruton tyrosine kinase inhibitor into first-line treatment.
Approval Was Based on BRUIN CLL-313
BRUIN CLL-313 was a global, randomized, open-label phase III trial enrolling 282 patients with previously untreated CLL/SLL without 17p deletion. Patients were randomized 1:1 to pirtobrutinib 200 mg orally once daily until disease progression or unacceptable toxicity, or to BR. The primary endpoint was progression-free survival assessed by a blinded independent review committee. Secondary endpoints included response, duration of response, overall survival, time to next treatment, safety, and patient-reported outcomes.
The results can’t be extrapolated to previously untreated patients with known del(17p), a biologically high-risk group that needs separate evidence.
Pirtobrutinib is a highly selective non-covalent BTK inhibitor that binds both wild-type and C481-mutated BTK. That mechanism made it useful after covalent BTK inhibitor exposure, when acquired BTK alterations can lead to resistance. BRUIN CLL-313 tested the same drug before that selective pressure occurs.
Pirtobrutinib Significantly Improved Progression-Free Survival
At a median follow-up of 28 months, pirtobrutinib significantly improved independent review committee-assessed PFS compared with BR, with an 80% relative reduction in the risk of progression or death. Median PFS had not been reached with pirtobrutinib and was 33.5 months with BR.
The overall response rate was 94% with pirtobrutinib and 81% with BR. Complete responses were reported in 13% and 21%, respectively, with partial responses accounting for most responses in the pirtobrutinib group. Overall survival and the durability of disease control will need longer follow-up.
What the BR Comparator Means for Clinical Interpretation
BR is an active historical CLL regimen, but BTK inhibitors and fixed-duration venetoclax-based combinations have reduced the role of chemoimmunotherapy, particularly in older patients.
BRUIN CLL-313 provides randomized phase III evidence that first-line pirtobrutinib is superior to BR in patients without 17p deletion. It includes no head-to-head comparison with acalabrutinib, zanubrutinib, venetoclax-obinutuzumab, or newer targeted combinations. Choosing among these strategies still depends on continuous versus fixed-duration therapy, cardiovascular risk, drug interactions, comorbidities, molecular risk, and patient preference.
A separate phase III trial, BRUIN CLL-314, is comparing pirtobrutinib directly with ibrutinib in a BTK inhibitor-naive population that includes both treatment-naive and previously treated patients. The BRUIN program also includes randomized studies of pirtobrutinib after covalent BTK inhibition and in fixed-duration venetoclax-containing therapy.
Safety Remained Consistent With the Known Pirtobrutinib Profile
In BRUIN CLL-313, serious adverse reactions occurred in 28% of patients receiving pirtobrutinib. Adverse reactions led to dose reduction in 3.6% and permanent discontinuation in 4.3%.
Atrial fibrillation or flutter occurred in 1.4% of pirtobrutinib-treated patients. Cardiovascular toxicity has been an important consideration with BTK inhibition, but the trial excluded patients with significant cardiovascular disease, so the low rate may not apply to less-selected populations.
Across the broader pirtobrutinib program, the prescribing information includes warnings for serious infections, hemorrhage, cytopenias, cardiac arrhythmias, second primary malignancies, and hepatotoxicity including drug-induced liver injury. These matter more in an earlier-line population potentially facing prolonged exposure.
First-Line Use Raises Sequencing and Duration Questions
Using pirtobrutinib first means clinicians need evidence on subsequent covalent BTK inhibition, BCL2 inhibition, and other therapies after progression on a non-covalent BTK inhibitor. The consequences of choosing a non-covalent BTK inhibitor as the first BTK-directed therapy may differ from the better-established sequence.
Pirtobrutinib in BRUIN CLL-313 was given continuously until progression or unacceptable toxicity. That is a different treatment model from fixed-duration venetoclax-containing regimens, where a defined treatment-free interval is part of the strategy.
You can also read:
